Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.

In addition, these findings may be significant for synergizing anti-miR10b nanodrug with a standard of care in first-in-human clinical trials where testing it as a monotherapy is not likely.

also in 13,097 other papers